TG Therapeutics, Inc. to Present at Upcoming Investment Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Sees Strong Results in 2016
March 8, 2016 11:41 AM ESTRoth Capital reaffirms TG Therapeutics (Nasdaq: TGTX) with a Buy (and Focus Pick) rating and $33 price target following the company's FY15 results report, which was made late Monday.
Joseph Pantginis, Ph.D., commented, The GENUINE Phase III (under SPA) is now enrolling at >150 U.S. sites and complete enrollment is expected by year-end and top-line data in early 2017. TG... More
TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share
March 7, 2016 4:03 PM ESTTG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More